Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarstons Regulatory News (MARS)

Share Price Information for Marstons (MARS)

Share Price is delayed by 15 minutes
Get Live Data
45.85    0.05 (0.11%)
Bid:
45.60
Ask:
45.90
Spread: 0.30 (0.658%)
Market Cap: £290.17m
MARS Live PriceLast checked at - London Stock Exchange

Intraday Marstons Share Chart

Form 8.3 - The Vanguard Group, Inc.: Marston's plc

8 Feb 2021 14:48

The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Marston's plc 08-Feb-2021 / 14:48 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


FORM 8.3

Β 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

Β 

1.Β KEY INFORMATION

Β 

(a)Β Full name of discloser:

The Vanguard Group, Inc.

(b)Β Owner or controller of interests and short positions disclosed, if different from 1(a):

Β The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Β 

(c)Β Name of offeror/offeree in relation to whose relevant securities this form relates:

Β Use a separate form for each offeror/offeree

Marston's plc

(d)Β If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

Β 

(e)Β Date position held/dealing undertaken:

Β For an opening position disclosure, state the latest practicable date prior to the disclosure

04 February 2021

(f)Β In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

Β If it is a cash offer or possible cash offer, state "N/A"

N/A

Β 

2.Β POSITIONS OF THE PERSON MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a)Β Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Β 

Class of relevant security:

Β 

7.375p ordinary

Β 

Β 

Β 

Β 

Interests

Short positions

Β 

Number

%

Number

%

(1)Β Relevant securities owned and/or controlled:

21,055,933

3.32%

Β 

Β 

(2)Β Cash-settled derivatives:

Β 

Β 

Β 

Β 

Β 

(3)Β Stock-settled derivatives (including options) and agreements to purchase/sell:

Β 

Β 

Β 

Β 

Β 

Β TOTAL:

21,055,933

3.32%

Β 

Β 

Β 

Β 

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

(b)Β Rights to subscribe for new securities (including directors' and other employee options)

Β 

Class of relevant security in relation to which subscription right exists:

Β 

Details, including nature of the rights concerned and relevant percentages:

Β 

Β 

Β 

3.Β DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

(a)Β Purchases and sales

Β 

Class of relevant security

Purchase/sale

Β 

Number of securities

Price per unit

7.375p ordinary

BUY

9,990

0.97 GBP

Β 

Β (b)Β Cash-settled derivative transactions

Β 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(c)Β Stock-settled derivative transactions (including options)

Β 

(i)Β Writing, selling, purchasing or varying

Β 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(ii)Β Exercise

Β 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(d)Β Other dealings (including subscribing for new securities)

Β 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

4.Β OTHER INFORMATION

Β 

(a)Β Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

Β 

Β 

Β 

(b)Β Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i)Β the voting rights of any relevant securities under any option; or

(ii)Β the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

Β 

Β 

Β 

(c)Β Attachments

Β 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Β 

Β 

Date of disclosure:

8 February 2021

Contact name:

Shawn Acker

Telephone number:

001-610-669-8989

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.


Category Code:RET - Marston's plc
TIDM:
LEI Code:5493002789CX3L0CJP65
Sequence No.:93182
EQS News ID:1166804
Β 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
8th Jun 202011:48 amRNSPublication of Circular and Notice of GM
2nd Jun 20204:35 pmRNSPrice Monitoring Extension
29th May 202010:47 amRNSCOVID-19 Update Results Noteholder Consent Request
22nd May 20204:35 pmRNSPrice Monitoring Extension
22nd May 20201:35 pmRNSMarston’s and Carlsberg UK form JV Partnership
14th May 20207:00 amRNSCOVID-19 Financing and Dividend Update
7th May 202012:57 pmRNSCOVID-19 Update re: Noteholder Consent Request
4th May 202012:12 pmRNSChange to Interim Results Announcement Date
20th Apr 20207:00 amRNSCOVID-19 Update re: securitisation waiver granted
18th Mar 20207:00 amRNSCOVID-19 Update
17th Mar 202012:07 pmRNSSecond Price Monitoring Extn
17th Mar 202012:02 pmRNSPrice Monitoring Extension
3rd Feb 202012:51 pmRNSTotal Voting Rights
27th Jan 202010:19 amRNSResult of AGM
24th Jan 20207:00 amRNSTrading Update
10th Jan 20209:20 amRNSBlock listing Interim Review
2nd Jan 202011:43 amRNSTotal Voting Rights
27th Dec 20197:00 amRNSDirector Declaration
18th Dec 20194:28 pmRNSAnnual Financial Report
12th Dec 20193:52 pmRNSDirector/PDMR Shareholding
27th Nov 20197:00 amRNSPreliminary Results
25th Nov 20197:00 amRNSCompletion of Disposal
21st Nov 20192:52 pmRNSDirectorate Change
4th Nov 20197:00 amRNSDisposal
1st Nov 20192:24 pmRNSTotal Voting Rights
15th Oct 20197:00 amRNSYear End Trading Update
1st Oct 201910:05 amRNSTotal Voting Rights
2nd Sep 20192:15 pmRNSTotal Voting Rights
29th Jul 20197:00 amRNSBoard Changes
24th Jul 20197:00 amRNSTrading Update
10th Jul 201911:15 amRNSBlock listing Interim Review
17th Jun 20193:37 pmRNSDirector/PDMR Shareholding
15th May 20197:00 amRNSInterim results for 26 weeks ended 30 March 2019
4th Mar 201911:51 amRNSTotal Voting Rights
1st Feb 20199:11 amRNSTotal Voting Rights
24th Jan 201910:29 amRNSResult of AGM
23rd Jan 20197:00 amRNSTrading Update for the 16 weeks to 19 January 2019
11th Jan 20198:48 amRNSBlock listing Interim Review
2nd Jan 20192:20 pmRNSTotal Voting Rights
19th Dec 201811:04 amRNSAnnual Financial Report
13th Dec 20183:09 pmRNSDirector/PDMR Shareholding
13th Dec 20183:07 pmRNSDirector/PDMR Shareholding
21st Nov 20187:00 amRNSPreliminary Results
8th Nov 20188:46 amRNSHolding(s) in Company
6th Nov 20184:19 pmRNSHolding(s) in Company
2nd Nov 20182:39 pmRNSHolding(s) in Company
1st Nov 20183:35 pmRNSHolding(s) in Company
1st Nov 20181:25 pmRNSTotal Voting Rights
12th Oct 20184:07 pmRNSHolding(s) in Company
10th Oct 20187:00 amRNSYEAR END TRADING UPDATE

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.